Literature DB >> 10626152

Prognostic factors in multiple myeloma.

S V Rajkumar1, P R Greipp.   

Abstract

There is significant variation in the survival of patients with myeloma. This article reviews the major prognostic factors in myeloma and the evidence supporting their usefulness in clinical practice and research. The factors reviewed include serum beta 2-microglobulin, bone marrow plasma cell labeling index, cytogenetics, plasmablastic morphology, and other standard clinical laboratory variables. Novel factors such as bone marrow angiogenesis are also discussed. A combination of independent factors provides greater prognostic information than any one factor alone, and survival data using various combinations of prognostic factors are presented.

Entities:  

Mesh:

Year:  1999        PMID: 10626152     DOI: 10.1016/s0889-8588(05)70128-3

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  17 in total

Review 1.  Bone marrow immunohistology of plasma cell neoplasms.

Authors:  A Wei; S Juneja
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

2.  PI3K/p110{delta} is a novel therapeutic target in multiple myeloma.

Authors:  Hiroshi Ikeda; Teru Hideshima; Mariateresa Fulciniti; Giulia Perrone; Naoya Miura; Hiroshi Yasui; Yutaka Okawa; Tanyel Kiziltepe; Loredana Santo; Sonia Vallet; Diana Cristea; Elisabetta Calabrese; Gullu Gorgun; Noopur S Raje; Paul Richardson; Nikhil C Munshi; Brian J Lannutti; Kamal D Puri; Neill A Giese; Kenneth C Anderson
Journal:  Blood       Date:  2010-05-26       Impact factor: 22.113

3.  Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma.

Authors:  Grzegorz S Nowakowski; Thomas E Witzig; David Dingli; Michal J Tracz; Morie A Gertz; Martha Q Lacy; John A Lust; Angela Dispenzieri; Philip R Greipp; Robert A Kyle; S Vincent Rajkumar
Journal:  Blood       Date:  2005-06-16       Impact factor: 22.113

4.  Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival.

Authors:  Jeremy T Larsen; Cheng E Chee; John A Lust; Philip R Greipp; S Vincent Rajkumar
Journal:  Blood       Date:  2011-07-12       Impact factor: 22.113

5.  Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry.

Authors:  Samer Z Al-Quran; Lijun Yang; James M Magill; Raul C Braylan; Vonda K Douglas-Nikitin
Journal:  Hum Pathol       Date:  2007-08-21       Impact factor: 3.466

Review 6.  Multiple myeloma.

Authors:  S Vincent Rajkumar
Journal:  Curr Probl Cancer       Date:  2009 Jan-Feb       Impact factor: 3.187

7.  Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

Authors:  Nikhil C Munshi; Kenneth C Anderson; P Leif Bergsagel; John Shaughnessy; Antonio Palumbo; Brian Durie; Rafael Fonseca; A Keith Stewart; Jean-Luc Harousseau; Meletios Dimopoulos; Sundar Jagannath; Roman Hajek; Orhan Sezer; Robert Kyle; Pieter Sonneveld; Michele Cavo; S Vincent Rajkumar; Jesus San Miguel; John Crowley; Hervé Avet-Loiseau
Journal:  Blood       Date:  2011-02-03       Impact factor: 22.113

8.  A novel role of HLA class I in the pathology of medulloblastoma.

Authors:  Courtney Smith; Mariarita Santi; Bhargavi Rajan; Elisabeth J Rushing; Mi Rim Choi; Brian R Rood; Robert Cornelison; Tobey J MacDonald; Stanislav Vukmanovic
Journal:  J Transl Med       Date:  2009-07-12       Impact factor: 5.531

9.  Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy.

Authors:  Paul Richardson; Constantine Mitsiades; Jacob Laubach; Robert Schlossman; Irene Ghobrial; Teru Hideshima; Nikhil Munshi; Kenneth Anderson
Journal:  Core Evid       Date:  2010-06-15

10.  Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade.

Authors:  J L Xu; R Lai; T Kinoshita; N Nakashima; T Nagasaka
Journal:  J Clin Pathol       Date:  2002-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.